Mark Vaeck

Biography

Mark Vaeck co-founded Complix in 2008 and has been a member of the Board since its inception. In May 2010 he helped raising the Series A financing round of Complix and was elected CEO shortly thereafter. From June 2006 until April 2010 he has been the founding CEO of ActoGeniX, a biopharmaceutical company based in Ghent (Belgium) developing novel protein therapeutics formulated for oral delivery. As CEO of ActoGeniX he raised over 35 million Euro in two rounds of equity financing. From mid-2001 until May 2006 he served as CEO of Ablynx NV (Belgium), a EuroNext quoted biopharmaceutical company developing therapeutic antibody fragments (“Nanobodies”), which he co-founded in June 2001. As CEO of Ablynx he raised 30 million Euro in equity financing and concluded several corporate deals with major pharmaceutical companies. Prior to joining Ablynx he was Chief Operating Officer of Ceres Inc., a NASDAQ listed company based in California and focused on the development of innovative technologies for biofuel production. Between 1993 and 1998 he served as Director Business Development and thereafter as CEO of Keygene N.V., a biotechnology company in The Netherlands. Between 1983 and 1993 he held several management positions in the biotech and pharma industry, including Director Business Development at EuroCetus (Chiron Corp.), 

Research Interest

 During recent years he has also been serving as chairman of the BioWin jury, which reviews new life sciences projects funded by the regional government in Wallonia; and is a Board member of InteRNA, an emerging drug development company applying a proprietary microRNA based discovery platform. Dr. Vaeck received his PhD in Immunology in 1982 from the University of Brussels